Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2012 | 2 |
2013 | 2 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia.
Haematologica. 2013 Jan;98(1):65-70. doi: 10.3324/haematol.2012.070755. Epub 2012 Oct 12.
Haematologica. 2013.
PMID: 23065520
Free PMC article.
Fludarabine-cyclophosphamide-rituximab is the most efficient first-line treatment for chronic lymphocytic leukemia patients. Many dose adjustments of the original MD Anderson Cancer Center regimen have been proposed. However, whether fludarabine-cyclophosphamide-rituximab …
Fludarabine-cyclophosphamide-rituximab is the most efficient first-line treatment for chronic lymphocytic leukemia patients. Many dose adjus …
The oncologic impact of a delay between diagnosis and radical nephroureterectomy due to diagnostic ureteroscopy in upper urinary tract urothelial carcinomas: results from a large collaborative database.
Nison L, Rouprêt M, Bozzini G, Ouzzane A, Audenet F, Pignot G, Ruffion A, Cornu JN, Hurel S, Valeri A, Roumiguie M, Polguer T, Hoarau N, Mérigot de Treigny O, Xylinas E, Matte A, Droupy S, Fais PO, Descazeaud A, Colin P; MD for the French Collaborative National Database on UUT-UC.
Nison L, et al.
World J Urol. 2013 Feb;31(1):69-76. doi: 10.1007/s00345-012-0959-1. Epub 2012 Oct 16.
World J Urol. 2013.
PMID: 23070533
Item in Clipboard
Cite
Cite